Key facts
- Notable investors include Texas Medical Center, MassBio, ACS BrightEdge.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for TMAB Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for TMAB Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TMAB Therapeutics
Developer of monoclonal antibodies intended for overcoming anti-VEGF (Vascular Endothelial Growth Factor) treatment resistance in certain cancers. The company's platform works to develop antibodies targeting resistance mechanisms in ovarian, endometrial, brain, and colorectal cancers, enabling oncology patients facing treatment resistance to potentially access effective therapies and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2023
- Employees
- 4
- Website
- tmabtherapeutics.com/
- Ownership
- Privately Held (backing)
TMAB Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TMAB Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TMAB Therapeutics in its N-PORT filings yet. We sweep new filings monthly.